The US Food and Drug Administration (FDA) has approved a new drug for treating adult and childhood cancer patients based on genetic mutations rather than on type of disease.
The drug is called Vitrakvi and its scientific name LAROTECTINIB has been approved for the treatment of cancer that occurs anywhere in the body.
NITCAVI is the first drug designed initially to combat the genetic mutation of the disease, no matter what type of cancer, NBC said.
FDA approval is an important step in the treatment of cancer, says FDA Commissioner Scott Gottlieb in a statement. "The reason for tumor genes, no matter where they originate from the body".
"This will help patients get" quick treatment, "he said.
He said that the drug treats people with different tumors but has a common genetic mutation and notes that this was not available a decade ago since knowledge about genetic mutations was then less than it is now.